Trinity Is Recognized in the Gartner® Hype Cycle™ for Intelligent Health, 2026

Transformational, in our view, is the highest benefit rating Gartner assigns in its Hype Cycle research. We feel It indicates that Gartner believes this technology has the potential to fundamentally change the way organizations operate and deliver value — not just improve existing processes but redefine them. For healthcare and life sciences, we believe Gartner specifically calls out DToP’s potential to enhance predictive analytics, accelerate drug discovery and development, enable personalization of treatments, and improve patient outcomes at scale.

In Gartner Hype Cycle reports, to us, sample Vendors are organizations that Gartner identifies as representative players in a given technology category. We believe that Inclusion indicates that Gartner research team has identified Trinity as a relevant participant in the Digital Twin of a Person space within healthcare and life sciences. It is a signal of market presence and capability, not a ranking or endorsement. Gartner notes: “Gartner does not endorse any vendor, product or service depicted in its research publications.”

Trinity’s digital twin solutions are built for the specific evidence and commercial rigor of the life sciences industry, and held to our ART standard — Accurate, Relevant, and Transparent on Accuracy. This means our models are grounded in validated real-world evidence (not synthetic proxies), purpose-built for the decisions they are meant to inform (commercial forecasting, clinical trial design, market access modeling), and fully transparent about confidence levels, data provenance, and model limitations. In an industry where decisions carry regulatory, clinical, and commercial consequences, transparency is foundational.

In our view, The Hype Cycle for Intelligent Health, 2026 is written primarily for HCLS CIOs and technology strategy leaders. However, its content is directly relevant to a broader audience including Chief Commercial Officers, VP/Directors of Strategy and Innovation, Brand and Market Access leaders, R&D and Clinical Operations leadership, and any life sciences professional responsible for evaluating and investing in AI, data, and digital health technologies. If you are planning a product launch, designing a clinical program, or building a multi-year digital strategy, this report has direct implications for your work.

When you complete the form, you will receive access to the complete Gartner Hype Cycle for Intelligent Health, 2026 report — all 104 pages, covering all 27 technologies and strategies analyzed, including the full Digital Twin of a Person in HCLS section (pages 25–28) in which Trinity is recognized.

Trinity applies digital twin and synthetic respondent capabilities across several stages of the pharmaceutical and biotech lifecycle, including: simulating patient populations to inform clinical trial design and enrollment targeting; building commercial forecasting models that test launch scenarios and payer access assumptions before market entry; generating synthetic respondent panels to accelerate market research timelines; and modeling competitive and market dynamics to support portfolio and brand strategy. We work with clients across therapeutic areas and development stages, from early pipeline through post-launch optimization.